Evidence map›Paper›PMID 42683794›Full record

ArticleJournal of clinical neurology (Seoul, Korea)2026

Effects of Glucagon-Like Peptide-1 Receptor Agonist Use After Transient Ischemic Attack on Risks of Subsequent Ischemic Stroke and Mortality.

Jay Kakadiya, Pranjal Rai, Girish Bathla, Vidhi Dhaduk, Huanwen Chen, Matthew K McIntyre, Daniel Mandel, Shahrzad Latifi, Brian Connolly, Hamza A Salim and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical neurology (Seoul, Korea), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Jay Kakadiya *Division of Neuroradiology, Department of Radiology and Radiological Sciences, Johns Hopkins University, Baltimore, MD, USA.ORCID https://orcid.org/0009-0009-2075-6562
Pranjal Rai *Department of Radiology, Mayo Clinic, Rochester, MN, USA.ORCID https://orcid.org/0009-0008-3796-8273
Girish BathlaDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.ORCID https://orcid.org/0000-0003-3170-242X
Vidhi DhadukDepartment of Neurology, Shantabaa Medical College and General Hospital, Amreli, Gujarat, India.ORCID https://orcid.org/0009-0007-3645-4054
Huanwen ChenDepartment of Neurosurgery, University of Maryland Medical Center, Baltimore, MD, USA.ORCID https://orcid.org/0000-0003-2455-748X
Matthew K McIntyreDepartment of Neurosurgery, Oregon Health and Science University, Portland, OR, USA.ORCID https://orcid.org/0009-0004-9788-5913
Daniel MandelDepartment of Neurology, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, USA.ORCID https://orcid.org/0000-0002-9484-4698
Shahrzad LatifiDepartment of Neuroscience, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, USA.ORCID https://orcid.org/0000-0002-1035-0974
Brian ConnollyDepartment of Neuroradiology, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, USA.
Hamza A SalimDepartment of Neuroradiology, MD Anderson Cancer Center, Houston, TX, USA.ORCID https://orcid.org/0000-0002-5208-8425
Ahmed Y AzzamDepartment of Neuroradiology, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, USA.ORCID https://orcid.org/0000-0002-4256-0159
Muhammed Amir EssibayiDepartment of Neurological Surgery, Montefiore Medical Center, The University Hospital for Albert Einstein College of Medicine, NY, USA.ORCID https://orcid.org/0000-0001-8325-2382
Vivek S YedavalliDivision of Neuroradiology, Department of Radiology and Radiological Sciences, Johns Hopkins University, Baltimore, MD, USA.ORCID https://orcid.org/0000-0002-2450-4014
Majid KhanDivision of Neuroradiology, Department of Radiology and Radiological Sciences, Johns Hopkins University, Baltimore, MD, USA.ORCID https://orcid.org/0000-0002-3807-1387
Adam A DmytriwNeuroendovascular Program, Massachusetts General Hospital & Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID https://orcid.org/0000-0003-0131-5699
David J AltschulDepartment of Neurological Surgery, Montefiore Medical Center, The University Hospital for Albert Einstein College of Medicine, NY, USA.ORCID https://orcid.org/0000-0002-5130-1378
Marco ColasurdoDepartment of Interventional Radiology, Oregon Health and Science University, Portland, OR, USA.ORCID https://orcid.org/0000-0002-7823-3088
Ajay MalhotraDepartment of Radiology, Yale New Haven Hospital, New Haven, CT, USA.ORCID https://orcid.org/0000-0001-9223-6640
Dheeraj GandhiDepartment of Neurosurgery, University of Maryland Medical Center, Baltimore, MD, USA.ORCID https://orcid.org/0000-0001-6741-5970
Dhairya A LakhaniDepartment of Neurology, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, USA.ORCID https://orcid.org/0000-0001-7577-1887

Funding

West Virginia IDEA-CTRU54GM104942 · NIGMS · WEST VIRGINIA UNIVERSITY · PI JUDITH FEINBERG · 2012 to 2026
$81.0M
NIGMS NIH HHS U54 GM104942
6 · The paper itself

Abstract

background and purposeA transient ischemic attack (TIA) is associated with a markedly higher risk of subsequent ischemic stroke even when guideline-directed prevention strategies are applied. There is evidence emerging from the LAMP trial that glucagon-like peptide-1 receptor agonists (GLP-1RAs) can help to prevent secondary stroke. We therefore conducted this study to evaluate the association in a real-world cohort.

methodsWe conducted a retrospective cohort study using data from the TriNetX US Collaborative Network. Adults with TIA who received antithrombotic therapy between 7 days before and 7 days after a TIA diagnosis were included. GLP-1RA use was defined as its initiation between 3 months before to 7 days after a TIA diagnosis. Propensity-score matching (PSM) was performed at a 1:1 ratio to balance covariates. The primary outcomes were ischemic stroke and mortality, while the secondary outcomes were inpatient (IP) admissions and emergency department (ED) visits. Outcomes were assessed over a 5-year follow-up period. Sensitivity analyses stratified by body mass index, hemoglobin-A1c level, and atrial fibrillation status were conducted to generalize the findings.

resultsAfter applying PSM, 5,071 GLP-1RA users and 5,071 GLP-1RA nonusers were included. GLP-1RA use was associated with lower risks of ischemic stroke (6.9% vs. 10.9%, hazard ratio [HR]=0.76,

conclusionsGLP-1RA is associated with lower risks of ischemic stroke, mortality, IP admissions, and ED visits in TIA patients. These preliminary findings suggest that GLP-1RAs can play a role in the secondary prevention of cerebrovascular disease.

Indexed as

glucagon-like peptide-1 receptor agonistsischemic strokemortalitytransient ischemic attackTriNetX

Identifiers

PMID42683794
PMCPMC13553170

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.